Wedbush Starts Spring Works Therapeutics (SWTX) at Outperform

Go back to Wedbush Starts Spring Works Therapeutics (SWTX) at Outperform

Cowen Starts Spring Works Therapeutics (SWTX) at Outperform

October 8, 2019 5:35 AM EDT

Cowen analyst Yaron Werber initiates coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Outperform rating.

The analyst comments "SpringWorks is focused on genetic targets in rare tumors and will have five programs in the clinic by Q1:20. Nirogacestat is in Ph3 in... More

Goldman Sachs Starts Spring Works Therapeutics (SWTX) at Buy

October 8, 2019 4:12 AM EDT

Goldman Sachs analyst Paul Choi initiates coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Buy rating and a price target of $37.00.


For an analyst ratings summary and ratings history on Spring Works Therapeutics... More

JPMorgan Starts Spring Works Therapeutics (SWTX) at Overweight

October 8, 2019 4:11 AM EDT

JPMorgan analyst Anupam Rama initiates coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Overweight rating and a price target of $32.00.


For an analyst ratings summary and ratings history on Spring Works Therapeutics... More